Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07318792 · ClinicalTrials.gov registry record · Phase 2
Using TropoCells(R) Autologous Platelet-Rich Fibrin (PRF) to Treat Chronic Non-Healing Wounds
A Phase 2 study, sponsored by Estar Medical dba Medical Technologies.
- Not yet
- Registry status
- Phase 2
- Development phase
- 16
- Enrollment target
NCT07318792 is a Phase 2 study that has not yet begun recruiting, run by Estar Medical dba Medical Technologies. The registered enrollment target is 16 participants.
The verdict
NCT07318792, a Phase 2 study, has not yet begun recruiting, sponsored by Estar Medical dba Medical Technologies.
- NOT YET RECRUITING
- Registry status
- Phase 2
- Development phase
- 16 participants
- Enrollment target
Study Summary
Platelet-based therapies have been used to treat bony and soft tissue effects for more than 30 years. Tropocells® Autologous Platelet-Rich Fibrin (PRF) is being used to treat chronic, non-healing wounds, of a variety of types. This will help determine the safety and effective use of PRF in the treatment of soft tissue defects.
Interventions
- DEVICE Platelet-rich fibrin (PRF)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2026-01-01 |
| Est. Completion | 2026-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07318792
The ClinicalTrials.gov registry entry for NCT07318792 describes a study currently listed as not yet recruiting, categorized as Phase 2. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Estar Medical dba Medical Technologies, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Platelet-rich fibrin (PRF) is the first listed.
NCT07318792 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07318792 about?
NCT07318792 is a clinical study titled "Using TropoCells(R) Autologous Platelet-Rich Fibrin (PRF) to Treat Chronic Non-Healing Wounds". Platelet-based therapies have been used to treat bony and soft tissue effects for more than 30 years. Tropocells® Autologous Platelet-Rich Fibrin (PRF) is being used to treat chronic, non-healing wounds, of a variety of types. This will help determine the safety and effective use of PRF in the treat...
What is the current status of trial NCT07318792?
This trial is currently not yet recruiting. It is a Phase 2 study. The enrollment target is 16 participants. The study started on 2026-01-01. Estimated completion is 2026-12.
What interventions are being tested in trial NCT07318792?
The interventions under investigation include: Platelet-rich fibrin (PRF) (DEVICE).
Who is sponsoring clinical trial NCT07318792?
This trial is sponsored by Estar Medical dba Medical Technologies, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.